Severe ocular Mpox in person living with advanced HIV treated with extended course of tecovirimat

IF 2.8 3区医学 Q2 INFECTIOUS DISEASES

HIV Medicine Pub Date : 2024-05-09 DOI:10.1111/hiv.13656

Lottie Brown, Pippa Sargent, Meriam Islam, Catriona Downie, Ali Hassan, Geraldine O'Hara, Sam Douthwaite, Ranjababu Kulasegaram, Scott Robbie, Emma Aarons, Iain D. Milligan

{"title":"Severe ocular Mpox in person living with advanced HIV treated with extended course of tecovirimat","authors":"Lottie Brown, Pippa Sargent, Meriam Islam, Catriona Downie, Ali Hassan, Geraldine O'Hara, Sam Douthwaite, Ranjababu Kulasegaram, Scott Robbie, Emma Aarons, Iain D. Milligan","doi":"10.1111/hiv.13656","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>People living with HIV are disproportionately represented among people with severe mpox. Mild and self-limiting conjunctival involvement has been well-documented, and severe ocular complications, including keratitis, corneal scarring, and the associated loss of vision, are increasingly recognized. Tecovirimat is the first-line antiviral therapy for severe mpox, but data around the efficacy of systemic antiviral agents for mpox are limited, particularly in cases of ocular mpox.</p>\n </section>\n \n <section>\n \n <h3> Case Report</h3>\n \n <p>Here, we describe a case of sight-threatening necrotic blepharokeratoconjunctivitis in a person with advanced HIV, requiring an extended course of tecovirimat due to persistent mpox viral shedding for nearly 5 months.</p>\n </section>\n </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"25 9","pages":"1086-1090"},"PeriodicalIF":2.8000,"publicationDate":"2024-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.13656","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hiv.13656","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

People living with HIV are disproportionately represented among people with severe mpox. Mild and self-limiting conjunctival involvement has been well-documented, and severe ocular complications, including keratitis, corneal scarring, and the associated loss of vision, are increasingly recognized. Tecovirimat is the first-line antiviral therapy for severe mpox, but data around the efficacy of systemic antiviral agents for mpox are limited, particularly in cases of ocular mpox.

Case Report

Here, we describe a case of sight-threatening necrotic blepharokeratoconjunctivitis in a person with advanced HIV, requiring an extended course of tecovirimat due to persistent mpox viral shedding for nearly 5 months.

Abstract Image

查看原文本刊更多论文

接受特考韦瑞延长疗程治疗的晚期艾滋病病毒感染者出现严重眼部脓疱疮。

背景：艾滋病毒感染者在严重水痘患者中所占比例过高。轻度和自限性结膜受累已得到充分证实，而严重的眼部并发症，包括角膜炎、角膜瘢痕和相关的视力丧失，则日益得到认可。特考韦瑞是治疗严重水痘的一线抗病毒药物，但有关全身性抗病毒药物对水痘疗效的数据有限，尤其是在眼部水痘病例中：在此，我们描述了一例晚期艾滋病病毒感染者危及视力的坏死性睑角膜结膜炎病例，由于痘病毒持续脱落近 5 个月，患者需要延长替考韦酯的疗程。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

HIV Medicine 医学-传染病学

CiteScore

5.10

自引率

10.00%

发文量

167

审稿时长

6-12 weeks

期刊介绍： HIV Medicine aims to provide an alternative outlet for publication of international research papers in the field of HIV Medicine, embracing clinical, pharmocological, epidemiological, ethical, preclinical and in vitro studies. In addition, the journal will commission reviews and other feature articles. It will focus on evidence-based medicine as the mainstay of successful management of HIV and AIDS. The journal is specifically aimed at researchers and clinicians with responsibility for treating HIV seropositive patients.